At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 593 enrolled
Drug / intervention
Iloperidone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.
In Brief
A Phase 3 clinical trial evaluating Iloperidone, Ziprasidone, and 1 other intervention for Schizophrenia. Completed, enrolled 593 participants across 42 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesIndia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartNov 2005
Primary CompletionSep 2006
Study CompletionMar 2007
TodayJul 2026
First PostedNov 15, 2005
Enrollment StartNov 18, 2005
Primary CompletionSep 26, 2006
Study CompletionMar 21, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.6 years ago
Interventions
Iloperidonedrug
Ziprasidonedrug
Placebodrug